6 completed, 4 not yet recruiting, 3 recruiting, 1 active not recruiting. 15 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 6, Not yet recruiting 4, Recruiting 3, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Not yet recruiting 1, Withdrawn 1 |
Follow irinotecan sucrosofate: new trials by email Literature Review of irinotecan sucrosofate trials Research Report on irinotecan sucrosofate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy Tambotatug pelitecan, Liposomal irinotecan, 5 Fluorouracil - Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 3 | Not yet recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 320 | 2026-10-01 | 2026-09-04 |
| A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart, Irinotecan liposome + 5-FU/LV + Bevacizumab, Irinotecan + 5-FU/LV + Bevacizumab - Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan | Phase 2 / Phase 3 | Not yet recruiting | Hebei Medical University Fourth Hospital | 408 | 2026-05-20 | 2026-05-13 |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer Setidegrasib, Oxaliplatin, Leucovorin - Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 614 | 2026-02-17 | 2026-11-03 |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 356 | 2025-08-21 | 2026-08-25 |
| Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) RMC-6236, Gemcitabine, nab-paclitaxel - Pancreatic Cancer, PDAC | Phase 3 | Active not recruiting | Revolution Medicines, Inc. | 500 | 2024-10-16 | 2026-06-02 |
| Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer Liposomal Irinotecan, Oxaliplatin, S-1 - Pancreatic Cancer | Phase 3 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 408 | 2024-09-01 | 2024-08-27 |
| Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC liposomal irinotecan, 5-FU, LV - Esophageal Cancer | Phase 3 | Not yet recruiting | Rui-hua Xu, MD, PhD | 360 | 2024-08-01 | 2024-07-15 |
| Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases Anti-CEA CAR-T cells, gemcitabine/nab paclitaxel, NLIR+FU/FA - Malignant Tumor of Pancreas Metastatic to Liver | Phase 2 / Phase 3 | Withdrawn | Sorrento Therapeutics, Inc. | 2021-11-01 | 2022-04-01 | |
| A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment Irinotecan Liposomal Injection, Oxaliplatin, 5Fluorouracil - Metastatic Adenocarcinoma of the Pancreas | Phase 3 | Completed | Ipsen | 770 | 2020-02-11 | 2026-04-20 |
| Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC eryaspase, Gemcitabine plus Abraxane, Irinotecan plus 5-FU plus leucovorin - Pancreatic Adenocarcinoma | Phase 3 | Completed | ERYtech Pharma | 512 | 2018-09-15 | 2022-10-18 |
| Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer Irinotecan liposome injection, Topotecan - Small Cell Lung Cancer | Phase 3 | Completed | Ipsen | 491 | 2018-04-25 | 2025-02-19 |
| 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy Irinotecan Liposomal Injection [Onivyde] - Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 3 | Completed | AIO-Studien-gGmbH | 151 | 2018-03-31 | 2025-04-17 |
| Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer Oxaliplatin, Irinotecan, Leucovorin - Pancreatic Cancer | Phase 3 | Completed | Stanford University | 27 | 2013-08-14 | 2022-10-28 |
| Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer MM-398, 5 Fluorouracil, Leucovorin - Metastatic Pancreatic Cancer | Phase 3 | Completed | Merrimack Pharmaceuticals | 417 | 2011-11-01 | 2016-06-17 |
Pancreatic Neoplasms (9) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Neoplasms (1) · Small Cell Lung Carcinoma (1)
Ipsen (2) · AIO-Studien-gGmbH (1) · Astellas Pharma Global Development, Inc. (1) · CSPC Ouyi Pharmaceutical Co., Ltd. (1) · ERYtech Pharma (1) · Hebei Medical University Fourth Hospital (1) · MediLink Therapeutics (Suzhou) Co., Ltd. (1) · Merrimack Pharmaceuticals (1) · NRG Oncology (1) · Revolution Medicines, Inc. (1) · Rui-hua Xu, MD, PhD (1) · SWOG Cancer Research Network (1) · Sorrento Therapeutics, Inc. (1) · Stanford University (1)
United States (9) · France (6) · Germany (6) · Spain (5) · Brazil (4) · Canada (4) · China (4) · Italy (4) · South Korea (4) · United Kingdom (4) · Australia (3) · Hungary (3) · Taiwan (3) · Belgium (2) · Czechia (2)
Daniel T Chang (1) · Eliel Bayever, MD (1) · Manfred P. Lutz, Prof. Dr. (1) · Manuel Hidalgo, MD, PhD (1) · Nina N Sanford (1) · Pascal Hammel, MD, PhD (1) · Rachael A Safyan (1) · Ruihua Xu, Professor (1) · Ying Yan, MD MS (1)
PMID 26615328, PMID 30414528, PMID 30654298, PMID 30842038, PMID 31789476, PMID 31856081, PMID 33214082, PMID 35195913, PMID 37708904, PMID 38648575, PMID 40696453, PMID 41087530, PMID 41187298, PMID 42080361, PMID 42223072
2017 (1), 2018 (1), U10CA180868 (1), U10CA180888 (1)